Related Experiment Video
Updated: Mar 26, 2026

Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders
Published on: April 28, 2023
[Wilson disease: liver form]
Luis Guerra Montero1, Félix Ortega Álvarez1, Julia Sumire Umeres2
1Unidad de Trasplante de órganos y Tejidos, Hospital Nacional Ramiro Priale Priale. Huancayo, Perú.
Wilson disease (WD) is a rare genetic disorder causing toxic copper buildup. Early diagnosis and copper chelation therapy significantly improve patient prognosis, even with atypical liver presentation.
Area of Science:
- Genetics
- Metabolic Disorders
- Hepatology
Background:
- Wilson disease (WD) is an autosomal recessive genetic disorder characterized by excessive copper accumulation in organs like the liver and brain.
- WD typically presents with liver issues in younger individuals and neurological symptoms in later stages.
- Understanding WD's varied presentation is crucial for timely diagnosis and management.
Observation:
- A 21-year-old female presented with edematous ascites and liver cirrhosis, a less common initial presentation for WD.
- Despite the advanced liver disease, the patient exhibited no initial neurological symptoms.
- Diagnostic indicators included decreased serum ceruloplasmin and elevated 24-hour urinary copper excretion (cupruria).
Findings:
- The patient's presentation highlights that WD can manifest primarily with severe liver disease, such as cirrhosis with ascites, even in young adults.
- Laboratory findings of low serum ceruloplasmin and high cupruria are key diagnostic markers for WD.
- These findings underscore the importance of considering WD in undiagnosed chronic liver disease.
Implications:
- WD should be suspected in cases of chronic liver disease of unknown origin, especially when viral and autoimmune markers are negative.
- Prompt diagnosis and initiation of copper-chelating agents can lead to substantial clinical improvement.
- Early intervention in WD is critical for altering the disease course and improving long-term patient outcomes.
More Related Videos
06:26Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
11:04Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides
Published on: September 7, 2019
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Hepatic Portal System
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...